Grifols S.A. (GRFS) |
|
22.73 0.05 (0.22%)
|
12-12 16:00 |
|
Open: |
22.69 |
Pre. Close: |
22.68 |
|
High:
|
22.92 |
Low:
|
22.56 |
|
Volume:
|
1,116,321 |
Market Cap:
|
20612M |
|
|
|
|
Grifols SA is a pharmaceutical company. It primarily collects the liquid portion of human blood called plasma and then manufactures and sells plasma-derived products globally. It also operates diagnostics, hospital supplies, and raw materials businesses. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
23.194 - 23.308 |
23.308 - 23.401 |
|
Low:
|
22.126 - 22.28 |
22.28 - 22.406 |
|
Close:
|
22.464 - 22.698 |
22.698 - 22.887 |
|
Technical analysis |
as of: 2019-12-12 4:00:57 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 27.56 One year: 32.20 |
| Support: |
Support1: 22.14 Support2: 21.24 |
| Resistance: |
Resistance1: 23.60 Resistance2: 27.56 |
| Pivot: |
22.62  |
| Moving Average: |
MA(5): 22.80 MA(20): 22.46
MA(100): 21.42 MA(250): 20.15 |
| MACD: |
MACD(12,26): 0.33 Signal(9): 0.36 |
| Stochastic oscillator: |
%K(14,3): 52.83 %D(3): 54.64 |
| RSI: |
RSI(14): 59.05 |
| 52-week: |
High: 23.60 Low: 17.42 Change(%): 20.6 |
| Average Vol(K): |
3-Month: 116960 10-Days: 139876 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.GRFS has closed below upper band by 35.9%. Bollinger Bands are 29.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2019-12-12
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
BARCELONA, Dec. 12, 2019 /PRNewswire/ -- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company's first 20%…
2019-12-02
Global Blood Grouping Reagents Market 2020-2024 | Evolving Opportunities with DIAGAST and Grifols SA | Technavio
LONDON--(BUSINESS WIRE)-- #Biotechnology--Global blood grouping reagents market is poised to grow by USD 443.28 million during 2020-2024 at a CAGR of over 10% during the forecast period.
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
